Search Results
Your search for Blood matches 4627 pages
Showing 1101 - 1150Kombucha
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DipIOM, LAc, and Jyothirmai Gubili, MS, focus on...
Paradox Between Cost and Hematopoietic Cell Transplant Rate in Latin America
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Gregorio Jaimovich, MD, Director of the Bone Marrow Transplant Program at Favaloro University Hospital in Buenos Aires. Distinguished expert on radiation therapy and bone...
Adoptive Cell Therapy May Soon Be Available for Patients With Melanoma
Oncologists who treat patients with melanoma will need to become familiar with another immunotherapy approach. For refractory metastatic disease, adoptive cell therapy is on the horizon. “Adoptive cell therapy will offer additional hope for our patients with melanoma. We’ll likely be seeing this...
Bispecific Antibodies Find a Place in B-Cell Lymphoma Treatment
In relapsed or refractory B-cell lymphomas, bispecific T-cell engager antibodies are finding a place in the treatment algorithm, said Christopher Flowers, MD, MS, FASCO, Professor and Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, Houston. At the...
BRAF-Mutant Colorectal Cancer: Latest Findings for Targeted Treatment
The phase II ANCHOR CRC study, the largest prospective study of BRAF inhibitor–based therapy as first-line treatment of metastatic colorectal cancer, has met its primary endpoint, with 47.8% of patients with metastatic colorectal cancer responding to first-line treatment with encorafenib,...
First-Line Acalabrutinib, Venetoclax, and Obinutuzumab for Chronic Lymphocytic Leukemia
In a phase II study reported in The Lancet Oncology, Matthew S. Davids, MD, and colleagues found that first-line triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab produced measurable residual disease (MRD)-negative complete remission in a substantial proportion of patients ...
Long-Term Outcomes in JULIET Trial of Tisagenlecleucel for Relapsed or Refractory Aggressive B-Cell Lymphomas
As reported by Stephen J. Schuster, MD, and colleagues in The Lancet Oncology, long-term outcomes of the pivotal phase II JULIET trial showed overall and complete response rates of 53% and 39% in adult patients with relapsed or refractory aggressive B-cell lymphomas treated with the T-cell...
COVID-19 Lockdown May Be Associated With Higher Tumor Burden in Newly Diagnosed Patients With Metastatic Colorectal Cancer
In a French study reported in JAMA Network Open, Thierry et al found that tumor burden (assessed as plasma circulating tumor DNA [ctDNA]) was significantly higher among patients with newly diagnosed metastatic colorectal cancer screened for a clinical trial after vs before the first COVID-19...
Mortality Trends After Allogeneic Blood or Marrow Transplantation
In an analysis from a Blood or Marrow Transplant Survivor Study cohort reported in JAMA Oncology, Smita Bhatia, MD, MPH, and colleagues found that late mortality among patients undergoing allogeneic blood or marrow transplantation for hematologic malignancies has declined over the past 40 years,...
Expert Point of View: Jacqueline C. Barrientos, MD, MS
Invited discussant Jacqueline C. Barrientos, MD, MS, of Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell in Great Neck, New York, noted that, although both ibrutinib and venetoclax have shown superior results to chemotherapy, each drug is associated with toxicity....
Fixed-Dose, First-Line Ibrutinib/Venetoclax Combination Achieves Durable Remissions in CLL
The combination of fixed-duration, first-line treatment with ibrutinib plus venetoclax achieved complete responses in more than half of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), based on the primary analysis of the fixed-dose cohort of the phase II CAPTIVATE ...
OlympiA Trial: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early Breast Cancer
Adjuvant therapy with the PARP inhibitor olaparib for 1 year extended disease-free survival in patients with high-risk early-stage HER2-negative breast cancer with BRCA1/2 germline (inherited) mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented at the...
Atezolizumab Plus Chemotherapy in Patients With Advanced NSCLC and Brain Metastases
Patients with advanced non–small cell lung cancer (NSCLC) and brain metastases derived benefit from treatment with atezolizumab plus chemotherapy, according to findings from the multicenter phase II ATEZO-BRAIN/GECP 17/05 trial. The study was presented at the International Association for the Study ...
Rates of Adverse Reactions to the Moderna mRNA-1273 COVID-19 Vaccine in Patients With Cancer and Recent Radiotherapy
In an Italian single-center study reported in a letter in The Lancet Oncology, Scoccianti et al found that patients who underwent radiotherapy for cancer within the 6 months prior to receipt of the Moderna mRNA-1273 COVID-19 vaccine did not experience a difference in adverse reactions to the...
AUTO1: CAR T-Cell Product for Adult Patients With Relapsed or Refractory B-Cell ALL
In a phase I trial (ALLCAR19) reported in the Journal of Clinical Oncology, Roddie et al found that the fast off-rate autologous CD19 chimeric antigen receptor (CAR) T-cell therapy CAT19-41BB-Z—also known as AUTO1—was well tolerated and produced high remission rates in adults with relapsed or...
Novel Urine-Based Test Evaluated in Prostate Cancer Detection and Risk Stratification
In a validation study with data presented at the American Urological Association’s 2021 Annual Meeting, clinician-researchers reported that a new test (miR Sentinel PCC4 Test) may be able to detect and risk-classify prostate cancer at the molecular level with predictive accuracy based on a single...
COVID-19 Pandemic Spurs Quick Uptick in Telehealth Adoption, ASCO Provides Guidance for Oncologists
ASCO recently released a new set of standards and practice recommendations specific to telehealth in oncology.1 These new standards provide guidance for which patients can be seen through telehealth; the establishment of the doctor-physician relationship; the role of allied health professionals and ...
Treatment of Relapsed Myeloma: Options Include New Drugs, Novel Combinations
The treatment paradigm for multiple myeloma continues to evolve at a rapid pace with the introduction of new drugs and the development of drug combinations, particularly the initial approach to the treatment of newly diagnosed multiple myeloma.1 One major shift in the treatment of newly diagnosed...
Daratumumab and Hyaluronidase-fihj With Pomalidomide Plus Dexamethasone in Multiple Myeloma
On July 9, 2021, daratumumab and hyaluronidase-fihj was approved for use in combination with pomalidomide and dexamethasone (Pd) for treatment of adults with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.1 Supporting...
Pembrolizumab Combined With Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
On May 5, 2021, pembrolizumab was granted accelerated approval for use in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal...
Highlights From Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
“Progress lies not in enhancing what is, but in advancing toward what will be.” —Khalil Gibran The Combined Annual Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) were held virtually...
Effect of High-Intensity Interval Training on Biochemical Progression in Patients With Localized Prostate Cancer Under Active Surveillance
In a Canadian single-institution phase II study (ERASE) reported in JAMA Oncology, Kang et al found that increased exercise in the form of high-intensity interval training was associated with increased cardiorespiratory fitness and reductions in prostate-specific antigen (PSA) level, PSA velocity,...
Assumptions, Data … and More Questions!
I read with great interest the results from the phase II ZUMA-12 study of axicabtagene ciloleucel, presented during the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 But the results raised several questions for me. Axicabtagene ciloleucel, an autologous anti-CD19...
Study Suggests Demographic Enrollment Reporting Requirements for Acute Leukemia Clinical Trials Are Lacking
Requirements instituted to address racial and ethnic disparities in clinical trial enrollment did not lead to increased inclusion of Black and Hispanic participants in clinical acute leukemia research, according to a new study published by Andrew Hantel, MD, and colleagues in the journal Blood...
Cell-Free DNA Analysis to Distinguish Development of Malignant Peripheral Nerve Sheath Tumors From Plexiform Neurofibromas
The inherited condition neurofibromatosis type 1, or NF1, is responsible for the development of benign tumors that grow along the nerves; in some individuals, however, these benign tumors transform into aggressive and malignant peripheral nerve sheath tumors. Determining whether this transformation ...
Pembrolizumab/Entinostat for Metastatic Uveal Melanoma
In the phase II PEMDAC study, researchers showed that the combination of the PD-1 inhibitor pembrolizumab and the histone deacetylase (HDAC) inhibitor entinostat resulted in durable responses in a small group of patients with metastatic uveal melanoma. These findings were published by Ny et al in...
Study Explores Relationship Between Anti-CD20 Therapy and Reduced Responses to mRNA COVID-19 Vaccines
Patients with lymphoma or other lymphoid cancers should continue to take steps to protect themselves from COVID-19 even if they have been vaccinated against the disease, a new study by Jennifer Crombie, MD, and colleagues published in Blood Advances suggests. The study found that patients who had...
Prostate Cancer Diagnostics: Novel Approaches Are Leaving Conventional Imaging Behind
Advances in molecular imaging are having a big impact on prostate cancer management and outcomes, according to Ashesh B. Jani, MD, the James C. Kennedy Professor in Prostate Cancer, Department of Radiation Oncology at the Winship Cancer Institute of Emory University, Atlanta. Dr. Jani described his ...
Personalized Risk Prediction Model for Patients With Myelodysplastic Syndromes
As reported in the Journal of Clinical Oncology, Aziz Nazha, MD, and colleagues have developed a model for predicting the risk of disease progression for individual patients with myelodysplastic syndromes (MDS). To develop the prediction model for overall survival and leukemic transformation,...
Prostate Cancer Screening Using the Stockholm3 Screening Test With MRI-Guided Biopsy
In a Swedish prostate cancer screening trial (STHLM3-MRI) reported in The Lancet Oncology, Nordström et al found that use of the Stockholm3 screening test together with magnetic resonance imaging (MRI)-guided biopsy reduced overdetection of disease while preserving the ability to detect clinically...
Japanese Study Examines How Intervention Encourages Screening for Colorectal Cancer Among Patients With Schizophrenia
Cancer is a leading cause of mortality in patients with mental illnesses. Although individuals with mental illnesses are equally as vulnerable to cancer as the general population, they are at a much higher risk of cancer-related mortality. Owing to a lack of early screening in most cases, such...
Antihypertensive Medications May Improve Survival Among Patients With Stage I to III Colorectal Cancer
Commonly used blood pressure drugs may improve survival for patients with colorectal cancer, a recent study published by Balkrishnan et al in Cancer Medicine suggests. After reviewing outcomes of almost 14,000 patients with colorectal cancer, researchers determined that angiotensin-converting...
I’m a Two-Time Breast Cancer Survivor, and the Experience Has Been Life-Altering
Even before my breast cancer diagnosis in early 2002, the year was shaping up to be life-altering for me and my family. We had moved from Seattle to Houston for a new career opportunity for my husband and were just settling into our new home when I felt a pea-sized nodule in my left breast during a ...
Isatuximab-irfc in Relapsed or Refractory Multiple Myeloma
On March 31, 2021, the anti-CD38 monoclonal antibody isatuximab-irfc was approved for use in combination with carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.1 Supporting Efficacy Data...
Combination of Lenvatinib and Etoposide/Ifosfamide for Relapsed or Refractory Osteosarcoma
In the phase I/II ITCC-050 trial reported in The Lancet Oncology, Gaspar et al found that the combination of lenvatinib with etoposide/ifosfamide showed antitumor activity, including good progression-free survival outcomes, in patients with relapsed or refractory osteosarcoma. Study Details...
Outcomes Notably Improving for Adult ALL
Outcomes in adults with acute lymphoblastic leukemia (ALL) are almost rivaling those in pediatric ALL, thanks to the benefits achieved by incorporating blinatumomab and inotuzumab into chemotherapy regimens. New ways of administering the chemotherapy component are also increasing tolerability and...
Gut Microbiome and Cancer
In recent years, the gut microbiome has garnered considerable attention as a scientific field, with far-reaching potential for clinical good. The trillions of microorganisms that inhabit the digestive tract form an incredibly complex community, which participates in countless interactions with its...
Do Muscle-Strengthening Activities Plus Aerobic Activities Reduce Cancer Mortality?
Regular muscle-strengthening exercises associated with aerobic activities can reduce cancer mortality, according to a systematic review of epidemiologic studies published by Nascimento et al in the International Journal of Behavioral Nutrition and Physical Activity. Workouts with activities like...
Risk of Early Cardiac Toxicity With Posttransplantation Cyclophosphamide After HSCT
In a French single-center retrospective cohort study reported in JACC: CardioOncology, Duléry et al found that posttransplantation cyclophosphamide was associated with a significantly increased risk of early cardiac events among patients receiving allogeneic hematopoietic stem cell transplantation...
Ribociclib Plus Topotecan/Temozolomide or Everolimus in Pediatric Patients With Advanced Cancer Enriched for Target Pathway Alterations
In a European platform trial (AcSé-ESMART) reported in the Journal of Clinical Oncology, Bautista et al found evidence of activity of the CDK4/6 inhibitor ribociclib plus the mTOR inhibitor everolimus in a population of children with recurrent or refractory malignancies enriched for alterations in...
2021 ASCO Annual Meeting: Next-Generation Oncology Highlights
The 2021 ASCO Annual Meeting was presented totally virtually again due to the persistence of the COVID-19 pandemic. Nevertheless, the meeting held widespread interest, and we were able to attend an event with important changes for the practice of oncology. Compared with 2020, fewer “next-generation ...
Study Investigates Relationship Between Peanut Agglutinin and Cancer Metastasis
A study published by Wang et al in the journal Carcinogenesis has identified new factors accompanying previous findings that frequent consumption of peanuts by patients with cancer could increase the risk of metastasis. Relationship Examined The results show that peanut agglutinin—a...
Study Finds COVID-19 Vaccine Is Safe in Patients With Hematologic Malignancies, but 25% of These Patients Do Not Produce Detectable Antibodies
About one in four patients with blood cancer fail to produce detectable antibodies after COVID-19 vaccination, but results vary substantially by type of blood cancer, according to a study by Greenberger et al published in the journal Cancer Cell. Although earlier studies have shown that certain...
Facing the Trauma of Colorectal Cancer
I first noticed blood in my stool when I was in the 8th grade. My mom and I did an Internet search and were relieved to find that the cause was most likely nothing more serious than hemorrhoids, so I put the problem out of my mind. I played volleyball and had an active social life, and the...
2021 ASCO Annual Meeting: Next-Generation Oncology Highlights
The 2021 ASCO Annual Meeting was presented totally virtually again due to the persistence of the COVID-19 pandemic. Nevertheless, the meeting held widespread interest, and we were able to attend an event with important changes for the practice of oncology. Compared with 2020, fewer...
CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel gene therapies for resistant non-Hodgkin lymphomas (NHL), including...
Cutaneous HPV May Be a Predictor of Cutaneous Squamous Cell Carcinoma Risk
In an article published by Rollison et al in Cancer Research, researchers demonstrated a link between the presence of cutaneous human papillomavirus (HPV) and the incidence of cutaneous squamous cell carcinomas. They also identified key characteristics of infection that may contribute to...
Neoadjuvant Cabozantinib/Nivolumab May Make Resection Possible for Some Patients With Liver Cancer
A combination of the kinase inhibitor cabozantinib and the immunotherapy nivolumab may make curative surgery possible for some patients with liver cancer who would generally not be considered candidates for surgery, according to research published by Ho et al in Nature Cancer. Rates of Resection...
Impact of Nurse Navigation Program on Outcomes in Minority Patients With Aggressive Lymphoma
In a single-institution study reported in the journal Cancer, Hu et al found that use of a dedicated nurse navigation program contributed to redressing the recognized inequities in care and outcomes between minority patients and White patients with aggressive large B-cell lymphoma (LBCL). As...
Association of Baseline Fatigue With Survival and Adverse Events in Patients With Advanced Cancer
In an analysis of four SWOG clinical trials of patients with advanced cancer reported in JCO Oncology Practice, Mo et al found that clinically significant fatigue at baseline was associated with poorer survival and increased risk of severe adverse events. Study Details The analysis included data...
